The primary outcome will be the percentage of patients who achieve a pCR after a T-DXd treatment.49 Also, the ARIADNE trial (NCT05900206) is comparing T-DXd to standard preoperative treatment for three cycles in patients with non-metastatic HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.